Immune induction and therapeutic effects of regulatory T cells in liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2021.04.011

Abstract

Abstract:

Induction of immune tolerance has always been a major problem after liver transplantation. In recent years, regulatory T cells (Tregs) have been found to play an important role in maintaining autoimmune tolerance. On the one hand, Tregs maintain immune homeostasis through high expression of CD25 and cytotoxic T lymphocyte-associated antigen-4, and on the other hand, a large number of immunosuppressive molecules, IL-10, IL-35, TGF-β and cAMP, are expressed to reduce the immune response. Tregs can be effectively expanded by inducing expansion in vivo and expansion in vitro. The safety, effectiveness, and the efficacy of Tregs therapy and combination with immunosuppressive agents have become the focus of current clinical research. This article summarizes the application prospects of Tregs therapy from the above aspects.

Key words: Regulatory T cells, Liver transplantation, Clinical trials, Immune tolerance

Hua Liu, Yajun Chen, Jianping Gong. Immune induction and therapeutic effects of regulatory T cells in liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(04): 239-243.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2021.04.011

https://zhyzzz.cma-cmc.com.cn/EN/Y2021/V15/I04/239

Figures/Tables 1

References 40

1	Morris H, DeWolf S, Robins H, et al. Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients[J]. Sci Transl Med, 2015, 7(272): 272ra10.
2	Zimmerer JM, Horne PH, Fisher MG, et al. Unique CD8⁺ T cell-mediated immune responses primed in the liver[J]. Transplantation, 2016, 100(9): 1907-1915.
3	Feng S, Bucuvalas J. Tolerance after liver transplantation: Where are we？[J]. Liver Transpl, 2017, 23(12): 1601-1614.
4	Sánchez-Fueyo A, Whitehouse G, Grageda N, et al. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation[J]. Am J Transplant, 2020, 20(4): 1125-1136.
5	Whitehouse GP, Hope A, Sanchez-Fueyo A. Regulatory T-cell therapy in liver transplantation[J]. Transpl Int, 2017, 30(8): 776-784.
6	Vaikunthanathan T, Safinia N, Boardman D, et al. Regulatory T cells: tolerance induction in solid organ transplantation[J]. Clin Exp Immunol, 2017, 189(2): 197-210.
7	Halliday N, Williams C, Kennedy A, et al. CD86 is a selective CD28 ligand supporting FoxP3⁺ regulatory T cell homeostasis in the presence of high levels of CTLA-4[J]. Front Immunol, 2020, 11: 600000.
8	Heidari F, Ramezani A, Erfani N, et al. Indoleamine 2, 3-dioxygenase: A professional immunomodulator and its potential functions in immune related diseases[J]. Int Rev Immunol, 2020: 1-18.
9	Tang Q, Vincenti F. Transplant trials with Tregs: perils and promises[J]. J Clin Invest, 2017, 127(7): 2505-2512.
10	Safinia N, Grageda N, Scottà C, et al. Cell therapy in organ transplantation: Our experience on the clinical translation of regulatory T cells[J]. Front Immunol, 2018, 9: 354.
11	Ko MK, Shao H, Kaplan HJ, et al. CD73⁺ dendritic cells in cascading Th17 responses of experimental autoimmune uveitis-induced mice[J]. Front Immunol, 2020, 11: 601272.
12	Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance[J]. Immunity, 2007, 27(4): 635-646.
13	Okoye I, Xu L, Motamedi M, et al. Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors[J]. J Immunother Cancer, 2020, 8(2): e001849.
14	Ronca V, Wootton G, Milani C, et al. The immunological basis of liver allograft rejection[J]. Front Immunol, 2020, 11: 2155.
15	Alvarez-Salazar EK, Cortés-Hernández A, Arteaga-Cruz S, et al. Large-scale generation of human allospecific induced Tregs with functional stability for use in immunotherapy in transplantation[J]. Front Immunol, 2020, 11: 375.
16	Tran LM, Thomson AW. Detection and monitoring of regulatory immune cells following their adoptive transfer in organ transplantation[J]. Front Immunol, 2020, 11: 614578.
17	Golshayan D, Jiang S, Tsang J, et al. In vitro-expanded donor alloantigen-specific CD4⁺CD25⁺ regulatory T cells promote experimental transplantation tolerance[J]. Blood, 2007, 109(2): 827-835.
18	Ferreira LMR, Muller YD, Bluestone JA, et al. Next-generation regulatory T cell therapy[J]. Nat Rev Drug Discov, 2019, 18(10): 749-769.
19	Del Papa B, Ruggeri L, Urbani E, et al. Clinical-grade-expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell-dependent graft-versus-leukemia effect in murine models[J]. Biol Blood Marrow Transplant, 2017, 23(11): 1847-1851.
20	Veerapathran A, Pidala J, Beato F, et al. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly[J]. Blood, 2011, 118(20): 5671-5680.
21	Lee K, Nguyen V, Lee KM, et al. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy[J]. Am J Transplant, 2014, 14(1): 27-38.
22	Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor[J]. Am J Transplant, 2017, 17(4): 917-930.
23	MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor[J]. J Clin Invest, 2016, 126(4): 1413-1424.
24	Boardman DA, Philippeos C, Fruhwirth GO, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection[J]. Am J Transplant, 2017, 17(4): 931-943.
25	Ward NC, Yu A, Moro A, et al. IL-2/CD25: A long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells [J]. J Immunol, 2018, 201(9): 2579-2592.
26	Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease[J]. Sci Transl Med, 2013, 5(179): 179ra43.
27	Whitehouse G, Gray E, Mastoridis S, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors[J]. Proc Natl Acad Sci U S A, 2017, 114(27): 7083-7088.
28	Thomson AW, Humar A, Lakkis FG, et al. Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies[J]. Hum Immunol, 2018, 79(5): 314-321.
29	Rickert CG, Markmann JF. Current state of organ transplant tolerance[J]. Curr Opin Organ Transplant, 2019, 24(4): 441-450.
30	Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3⁺ T cells into TH17 cells in autoimmune arthritis[J]. Nat Med, 2014, 20(1): 62-68.
31	Tripathi D, Cheekatla SS, Paidipally P, et al. C-Jun N-terminal kinase 1 defective CD4⁺CD25⁺FoxP3⁺ cells prolong islet allograft survival in diabetic mice[J]. Sci Rep, 2018, 8(1): 3310.
32	Chen Z, Barbi J, Bu S, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3[J]. Immunity, 2013, 39(2): 272-285.
33	Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2): 632-643.
34	Du X, Chang S, Guo W, et al. Progress in liver transplant tolerance and tolerance inducing cellular therapies [J]. Front Immunol, 2020, 11: 1326.
35	Mathew JM, H-Voss J, LeFever A, et al. A phase Ⅰ clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants[J]. Sci Rep, 2018, 8(1): 7428.
36	Chandran S, Tang Q, Sarwal M, et al. Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants[J]. Am J Transplant, 2017, 17(11): 2945-2954.
37	Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up[J]. Clin Immunol, 2014, 153(1): 23-30.
38	Di Ianni M, Falzetti F, Carotti A, et al. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation[J]. Best Pract Res Clin Haematol, 2011, 24(3): 459-466.
39	Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse[J]. Blood, 2014, 124(4): 638-644.
40	Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn′s disease[J]. Gastroenterology, 2012, 143(5): 1207-1217.

疾病	注册号	国家	设计方案	治疗剂量	状态
肝移植	NCT02188719	美国	4种剂量的Tregs与免疫抑制剂联用	(25~96)×10⁶个	已终止，有结果
肝移植	NCT02166177	英国	静脉输注Tregs	(0.5~6.5)×10⁶个/kg	已完成
肝移植	NCT02474199	美国	静脉输注Tregs后停用免疫抑制剂	(300~500)×10⁶个	已完成
肝移植	NCT01624077	中国	静脉输注Tregs	1×10⁶个/kg	未知
肾移植	NCT02145325	美国	静脉输注Tregs	(0.5~5)×10⁹个	已完成
1型糖尿病	ISRCTN06128462	波兰	静脉输注Tregs	30×10⁶个/kg	已完成

疾病	注册号	国家	设计方案	治疗剂量	状态
肝移植	NCT02188719	美国	4种剂量的Tregs与免疫抑制剂联用	(25~96)×10⁶个	已终止，有结果
肝移植	NCT02166177	英国	静脉输注Tregs	(0.5~6.5)×10⁶个/kg	已完成
肝移植	NCT02474199	美国	静脉输注Tregs后停用免疫抑制剂	(300~500)×10⁶个	已完成
肝移植	NCT01624077	中国	静脉输注Tregs	1×10⁶个/kg	未知
肾移植	NCT02145325	美国	静脉输注Tregs	(0.5~5)×10⁹个	已完成
1型糖尿病	ISRCTN06128462	波兰	静脉输注Tregs	30×10⁶个/kg	已完成

[1]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[2]	Jian Cui, Qing Dai. The relationship between the proportion of Treg cells and anaphylaxis was studied based on anaphylaxis model induced by hepatic cystic echinococcosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 427-430.
[3]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[4]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[5]	Tieyan Fan, Jun Li, Hong Chen. Diagnosis and treatment experience of new onset viral hepatitis E after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 293-296.
[6]	Shuo Chen, Feng Chen, Fei Cheng, Jie Xiang. Pancreas infarction after liver transplantation for glycogen storage disease type Ⅰ complicated with pancreatitis: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 300-302.
[7]	Penghao Tang, Wu Zhang. Progress in mechanism research about intestinal microecology with perioperative complications of liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 303-307.
[8]	Lina Zhu, Zizhen Yang, Di Zhang, Yong Zhang, Jinzhen Cai, Jianhong Wang. The application value of contrast-enhanced ultrasound in the diagnosis of hepatic artery complications after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 240-245.
[9]	Committee of Health Management for Organ Transplant Recipient, China Organ Transplantation Development Foundation, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Branch of Organ Transplant of Chinese Medical Association, National Center for Healthcare Quality Management in Liver Transplant. Chinese expert consensus on clinical application of inhibitors of mammalian target of rapamycin in liver transplant recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 193-204.
[10]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[11]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[12]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[13]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[14]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[15]	Xiaodong Wang, Kai Wang, Zhao Ge. Research progress of computer vision in improvement of therapeutic effect of liver transplantation for liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 361-366.

Please choose a citation manager

Content to export